top of page
DNA 4_edited_edited.jpg
odeo (1).png

Testing for RET

A free webinar series for endocrinologists and other healthcare professionals

Not an approved CE Course

Welcome to our webinar series on RET-driven cancers. The RET gene plays a crucial role in the development and function of the nervous system and endocrine system, and mutations in this gene can increase the risk of developing cancer. In this webinar series, we will delve into the relationship between RET gene alterations and cancer, focusing on the types of cancer that are most commonly associated with these alterations, such as medullary thyroid cancer and multiple endocrine neoplasia type 2. We will also discuss the latest research on the testing and treatment of RET gene mutation-associated cancer, including emerging therapies such as NTRK inhibitors. Whether you are a healthcare professional, a patient, or simply interested in learning more about this important topic, we hope that you will find this series informative and engaging. Let's get started!

Featured Speakers


Molecular Testing in Thyroid Cancer: Why It Matters

Lori J. Wirth, MD


Genetic and Genomic Testing in Thyroid Cancer: Why, when, who and how?

Bryan McIver, MD, PhD

Cohen-Ezra head shot.jpg

Molecular Testing in Thyroid Cancer: Emerging Biomarkers RET and NTRK

Ezra E.W. Cohen, MD, FRCPSC, FASCO


Thyroid Carcinomas with RET?  You bet!

Justin Bishop, MD

2016-03 UCSAP Lester D R Thompson.jpg

Selected Thyroid Follicular Lesions

Lester D. R. Thompson, MD

RET Fusions in Thyroid Cancer:
Prevalence, Histologic Features, Detection

Yuri E. Nikiforov, MD, PhD

Testing for RET is provided by Lighthouse, a Celerity Biosciences Subsidiary, and Funded by Loxo Oncology at Lilly

bottom of page